Figure 3.
![aGVHD II-IV. (A) We observed a tendency towards less aGVHD in patients having MSD (P = .071). (B) Patients receiving allo-HSCT during infancy (<13 months) suffered significanlty less aGVHD than older patients (P = .008). (C) A matched CMV serostatus correlated to less aGVHD (P = .018). (D) Predicted OS in patients according to patients’ aGVHD at day 30. The survival probability of OS was significatly reduced in patients developing aGVHD II-IV by day 30 (HR = 3.6 [95% CI 1.43-9.14]; P = .006).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/5/1/10.1182_bloodadvances.2020002185/2/advancesadv2020002185f3.png?Expires=1724238907&Signature=bE7SgNREY~Y2g2cnRtD1kMcBqzTxjnnpbFoYNQwFeMgP9kfrjTUvrWbRuFeo-WG0izGCMnvgCG9KurWYuk1QgZEWL3gfiz1yBWSGcGEwuH7UkxI88LC23uck4gFKRQssdAvy54CgR7VuWYtCuv6s~O9LqOUqjL66GHjoxfFNNyjbPU26EW~K0tUpNILdOk~tX2vWvHLDFh3~IjGsNITUWr4hrSfIoJNYnSr5C2X4EsJOdVhmPahWnZaKE0yDZR7wDuCwWIokJske33o2mz9OZbyZcwEWmxhLxb2mtpO3u0obNHZ0O4~D2i7sq5TMV~USUd0v9DLOij5uJizITh~dkg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
aGVHD II-IV. (A) We observed a tendency towards less aGVHD in patients having MSD (P = .071). (B) Patients receiving allo-HSCT during infancy (<13 months) suffered significanlty less aGVHD than older patients (P = .008). (C) A matched CMV serostatus correlated to less aGVHD (P = .018). (D) Predicted OS in patients according to patients’ aGVHD at day 30. The survival probability of OS was significatly reduced in patients developing aGVHD II-IV by day 30 (HR = 3.6 [95% CI 1.43-9.14]; P = .006).